{
    "2020-11-15": [
        [
            {
                "time": "",
                "original_text": "君实生物五年多亏超30亿，遭质疑或影响主打产品医保谈判，亏损",
                "features": {
                    "keywords": [
                        "君实生物",
                        "亏损",
                        "医保谈判",
                        "质疑"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【浙商医药|周报】估值持续回落，mRNA疫苗积极结果导致板块分化",
                "features": {
                    "keywords": [
                        "浙商医药",
                        "mRNA疫苗",
                        "估值回落",
                        "板块分化"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "招商策略：中期A股有望迎来一轮明显的“跨年行情”",
                "features": {
                    "keywords": [
                        "招商策略",
                        "A股",
                        "跨年行情"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "A股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "君实生物深夜回复交易所问询，港股股价收盘已转涨，问询",
                "features": {
                    "keywords": [
                        "君实生物",
                        "问询",
                        "港股",
                        "股价转涨"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【中金医药】疫苗突破+美国大选进展，行业调整与继续分化 - 中金医药周报系列七十九",
                "features": {
                    "keywords": [
                        "中金医药",
                        "疫苗突破",
                        "美国大选",
                        "行业调整",
                        "分化"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "高瓴加持也烫手？君实生物遭质疑股价大跌，市值蒸发超500亿，连续下跌",
                "features": {
                    "keywords": [
                        "高瓴",
                        "君实生物",
                        "质疑",
                        "股价大跌",
                        "市值蒸发"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【华泰金工林晓明团队】华夏养老2045今年以来收益38%——FOF投资周报20201115",
                "features": {
                    "keywords": [
                        "华泰金工",
                        "华夏养老2045",
                        "FOF投资",
                        "收益38%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "养老基金",
                        "FOF"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药行业每周医览药闻：中国科技创新的卖水者，科学服务行业方兴未艾",
                "features": {
                    "keywords": [
                        "医药行业",
                        "科技创新",
                        "科学服务",
                        "方兴未艾"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药",
                        "科学服务"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "生物医药行业周报：辉瑞新冠疫苗保护率超90%，新冠疫苗研发稳定推进",
                "features": {
                    "keywords": [
                        "生物医药",
                        "辉瑞",
                        "新冠疫苗",
                        "保护率90%",
                        "研发推进"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "疫苗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}